ZnT3 mRNA levels are reduced in Alzheimer's disease post-mortem brain
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background: ZnT3 is a membrane Zn 2+ transporter that is responsible for concentrating Zn 2+ into neuronal presynaptic vesicles. Zn 2+ homeostasis in the brain is relevant to Alzheimer's disease (AD) because Zn 2+ released during neurotransmission may bind to Aβ peptides, accelerating the assembly of Aβ into oligomers which have been shown to impair synaptic function. Results: We quantified ZnT3 mRNA levels in Braak-staged human post mortem (pm) brain tissue from medial temporal gyrus, superior occipital gyrus, superior parietal gyrus, superior frontal gyrus and cerebellum from individuals with AD (n = 28), and matched controls (n = 5) using quantitative real-time PCR. ZnT3 mRNA levels were significantly decreased in all four cortical regions examined in the AD patients, to 45-60% of control levels. This reduction was already apparent at Braak stage 4 in most cortical regions examined. Quantification of neuronal and glial-specific markers in the same samples (neuron-specific enolase, NSE; and glial fibrillary acidic protein, GFAP) indicated that loss of cortical ZnT3 expression was more pronounced, and occurred prior to, significant loss of NSE expression in the tissue. Significant increases in cortical GFAP expression were apparent as the disease progressed. No gene expression changes were observed in the cerebellum, which is relatively spared of AD neuropathology. Conclusions: This first study to quantify ZnT3 mRNA levels in human pm brain tissue from individuals with AD and controls has revealed a significant loss of ZnT3 expression in cortical regions, suggesting that neuronal cells in particular show reduced expression of ZnT3 mRNA in the disease. This suggests that altered neuronal Zn 2+ handling may be an early event in AD pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Hellemans, J., Mortier, G., De Paepe, A., Speleman, F., & Vandesompele, J. (2007) · Genome Biology · doi:10.1186/gb-2007-8-2-r19 · Cited by 4,023
Self-citationCopper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287 · cited 1×
“In addition, we identified increased GFAP expression in the AD pm brain tissue (cortical regions), reflecting the astrogliosis and astrocyte activation associated with the disease, as reported by others [39,40].”
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988 · cited 1×
“Compounds acting as metal ion chelators, such as clioquinol and PBT2, have entered clinical trials for AD. A slight improvement in clinical ratings was observed in twenty AD patients after a three week treatment with clioquinol [25], and it reduced plasma Aβ42 levels and increased Zn2+ levels in a phase two clinical t…”
Staging of Alzheimer-Related Cortical Destruction
Braak, H., Braak, E., & Bohl, J. (2008) · European Neurology · doi:10.1159/000116984 · Cited by 836 · cited 2×
“The reductions in cortical ZnT3 gene expression, by 45-60%, were already well-established at Braak stage 4, when neocortical regions are still relatively unaffected by AD-related neurofibrillary tangle pathology and overt neuronal loss [32].”
Deibel, M. A., Ehmann, W. D., & Markesbery, W. R. (1996) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(96)00203-1 · Cited by 540
Astrocyte phenotype in relation to Alzheimer‐type pathology in the ageing brain
Simpson, J. E., Ince, P. G., Lace, G., Forster, G., Shaw, P. J., Matthews, F., Savva, G., Brayne, C., & Wharton, S. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.015 · Cited by 381 · cited 1×
“In addition, we identified increased GFAP expression in the AD pm brain tissue (cortical regions), reflecting the astrogliosis and astrocyte activation associated with the disease, as reported by others [39, 40 ].”
Harrison, P. J., Heath, P. R., Eastwood, S. L., Burnet, P. W. J., McDonald, B., & Pearson, R. C. A. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12102-a · Cited by 342
Li, J. Z., Vawter, M. P., Walsh, D. M., Tomita, H., Evans, S. J., Choudary, P. V., Lopez, J. F., Avelar, A., Shokoohi, V., Chung, T., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh065 · Cited by 261
Cited by
Kambe, T., Tsuji, T., Hashimoto, A., & Itsumura, N. (2015) · Physiological Reviews · doi:10.1152/physrev.00035.2014 · Cited by 1,158
Metal dyshomeostasis and oxidative stress in Alzheimer’s disease
Greenough, M. A., Camakaris, J., & Bush, A. I. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.08.014 · Cited by 436
Brain Energy and Oxygen Metabolism: Emerging Role in Normal Function and Disease
Watts, M. E., Pocock, R., & Claudianos, C. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00216 · Cited by 411
Chen, B., Yu, P., Chan, W. N., Xie, F., Zhang, Y., Liang, L., Leung, K. T., Lo, K. W., Yu, J., Tse, G. M. K., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01679-y · Cited by 420
Adlard, P. A., Parncutt, J. M., Finkelstein, D. I., & Bush, A. I. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5255-09.2010 · Cited by 376
Metadata
- Authors
- Beyer, N., Coulson, D. T., Heggarty, S., Ravid, R., Irvine, G. B., Hellemans, J., & Johnston, J. A.
- Venue
- Molecular Neurodegeneration
- Published
- 2009-12
- Volume
- 4
- Issue
- 1
- Pages
- 53-53
- ISSN
- 1750-1326 (ISSN-L)
- OpenAlex
- W2103974087
- Cited by
- 67
- References
- 13
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ZnT3 mRNA levels are reduced in Alzheimer's disease post-mortem brain. https://app.cochat.ai/papers/10.1186/1750-1326-4-53
- The paper
- Beyer, N., Coulson, D. T., Heggarty, S., Ravid, R., Irvine, G. B., Hellemans, J., & Johnston, J. A. (2009). ZnT3 mRNA levels are reduced in Alzheimer's disease post-mortem brain. Molecular Neurodegeneration. https://doi.org/10.1186/1750-1326-4-53
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.